TOPAZ-1: Patient-Reported Outcomes From the Phase III Placebo-Controlled Trial of Durvalumab + Gemcitabine + Cisplatin for Advanced Biliary Tract Cancer

In addition to a previously reported overall survival benefit, durvalumab + gemcitabine/cisplatin was associated with a trend toward longer time to deterioration in global health status/quality of life for patients with advanced biliary tract cancer vs placebo + gemcitabine/cisplatin.